Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cancer vaccine

- PMLiVE

FDA approves SpringWork’s Ogsiveo as first therapy for desmoid tumours

Approximately 1,650 people in the US are diagnosed with the rare non-cancerous tumours each year

- PMLiVE

Cancer Research UK calls on government to create ten-year cancer plan

The charity estimates that around 20,000 annual cancer deaths in the UK could be prevented by 2040

- PMLiVE

AstraZeneca gains rights to Usynova’s KRAS inhibitor in deal worth almost $420m

There are currently no approved drugs specifically targeting the KRAS G12D mutation

- PMLiVE

Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m

The acquisition marks a significant boost to Boehringer’s immuno-oncology portfolio

EU flag

EC approves pharmaand’s Rubraca as advanced ovarian cancer maintenance treatment

An estimated 66,000 new cases of ovarian cancer are diagnosed in Europe each year

- PMLiVE

Merck receives FDA approval for Keytruda combination in gastric cancer

An estimated 26,500 people in the US will be diagnosed with gastric cancer in 2023

- PMLiVE

Bristol Myers Squibb’s lung cancer drug Augtyro receives FDA approval

The drug was added to BMS’ portfolio last year through its $4.1bn acquisition of Turning Point

- PMLiVE

Novartis gains global rights to Legend’s CAR-T cell therapies in deal worth over $1bn

Novartis can apply its T-Charge platform to the manufacturing process of the therapies

- PMLiVE

New genetic variants linked to prostate cancer in men with African ancestry

A dataset was compiled for the research containing DNA from over 944,000 men

- PMLiVE

AstraZeneca shares positive phase 3 results for Imfinzi combination in liver cancer

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

- PMLiVE

Roche’s subcutaneous Tecentriq recommended by CHMP for multiple cancer types

The formulation can cut treatment time by approximately 80% compared to intravenous infusion

- PMLiVE

Merck’s Keytruda combination receives CHMP recommendation for biliary tract cancer

Approximately 211,000 people are diagnosed with the disease globally each year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links